MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on July 29, 2008; DOI: 10.1124/mol.108.048819


0026-895X/08/7404-1163-1169$20.00
Mol Pharmacol 74:1163-1169, 2008

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
mol.108.048819v1
74/4/1163    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zhang, Y.
Right arrow Articles by Green, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhang, Y.
Right arrow Articles by Green, T.

Mutations to the Kainate Receptor Subunit GluR6 Binding Pocket That Selectively Affect Domoate BindingFormula

Yihong Zhang1, Naushaba Nayeem, and Tim Green

Department of Pharmacology, School of Biomedical Sciences, University of Liverpool, Ashton Street, Liverpool, United Kingdom

Kainate receptor responses to domoate are characterized by large steady-state currents and slow deactivation kinetics. To improve our understanding of these responses, we mutated residues at the mouth of the agonist binding pocket of GluR6 using whole-cell electrophysiology to characterize the effects of the mutants. We identified two residues where mutations had significant ligand-specific effects. One, Met691, forms a hydrogen bond that seems to facilitate domoate binding by affecting the main-chain conformation. We found that mutation of Met691 to alanine significantly attenuated responses to domoate but had no effect on responses to glutamate, confirming the importance of this main-chain interaction in GluR6. The second residue, Val685, is located at the mouth of the binding pocket, adjacent to the domoate side-arm. Mutation of Val685 to glutamine increased the rate of decay from steady-state responses to domoate by more than 50-fold but had no effect on the rate or extent of desensitization or on the kinetics of responses to either glutamate or kainate. The V685Q mutant also significantly reduced the potencies of both glutamate (peak) and domoate (peak and steady-state). Empirical analysis using a basic kinetic model indicated that the V685Q phenotype could be fully explained by faster ligand dissociation. The V685Q mutant accelerated receptor deactivation without affecting either desensitization or gating, making it a potentially useful tool for further dissection of ligand binding and gating in kainate receptors.


Received May 16, 2008; accepted July 28, 2008

Address correspondence to: Tim Green, Department of Pharmacology, School of Biomedical Sciences, University of Liverpool, Ashton Street, Liverpool L69 3GE, UK. E-mail: tpgreen{at}liv.ac.uk







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics